Clinical Trial Detail

NCT ID NCT03669965
Title KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kartos Therapeutics, Inc.
Indications

polycythemia vera

Therapies

Ruxolitinib

KRT-232

Age Groups: senior adult

No variant requirements are available.